Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
Colorectal Cancer Stage IVMetastasis
Interventions
DRUG

Cetuximab plus FOLFIRI/FOLFOX

cetuximab was added into the routine perioperative chemotherapy(FOLFIRI/FOLFOX) to evaluate its safety and efficacy

DRUG

FOLFIRI/FOLFOX/CapeOX

to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)

Trial Locations (4)

100142

Beijing Cancer Hospital, Beijing

310022

Zhejiang Cancer Hospital, Hangzhou

610041

West China Hospital, Sichuan University, Chengdu

650032

First Affiliated Hospital of Kunming Medical University, Kunming

All Listed Sponsors
collaborator

Beijing Municipal Administration of Hospitals

OTHER_GOV

collaborator

West China Hospital

OTHER

collaborator

Zhejiang Cancer Hospital

OTHER

collaborator

First Affiliated Hospital of Kunming Medical University

OTHER

lead

Peking University Cancer Hospital & Institute

OTHER

NCT03031444 - Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis | Biotech Hunter | Biotech Hunter